
Triple-pathway fat loss
Every active named. Every dose stated. Nothing behind a blend.
| Active | Per day | Per pen |
|---|---|---|
| RetatrutideTriple receptor agonistAn investigational triple agonist acting at the GLP-1, GIP and glucagon receptors. Studied in metabolic research. | 21.1 mgper day | 6mg - 32mgper pen |
Also contains mannitol as a bulking agent and a sodium acetate buffer. Supplied lyophilised — reconstitute with the bacteriostatic water included in the kit.
The batch number on the certificate matches the number printed on your pen.
| Test | Method | Specification | Result |
|---|---|---|---|
| Retatrutide content | RP-HPLC | 6mg - 32mg | 633.6 mg Pass |
| Purity | RP-HPLC 214 nm | ≥ 98.0 % | 99.1 % Pass |
| Identity | ESI-MS | Conforms | Conforms Pass |
| Bacterial endotoxin | LAL kinetic | < 0.20 EU/mg | < 0.05 EU/mg Pass |
| Water content | Karl Fischer | ≤ 8.0 % | 3.1 % Pass |
| Heavy metals | ICP-MS | Within limits | Conforms Pass |
| Microbial limits | Plate count | < 100 CFU/g | < 10 CFU/g Pass |
Plain descriptions of the compounds and what they've been studied for. No claims about treating or curing anything.
An investigational triple agonist acting at the GLP-1, GIP and glucagon receptors. Studied in metabolic research.
Once-weekly titrated pen for fat loss and appetite control. Dose steps up month by month.
For anyone struggling with cravings, appetite control or fat-loss plateaus.